Sun Pharma & Bayer tie up to market new renal therapy

Sun Pharma and Bayer have entered into an agreement to market and distribute a second brand of the patented medicine Finerenone in India. Finerenone is designed to reduce the risk of various complications in adult patients with chronic kidney disease associated with type 2 diabetes mellitus. Under the deal, Bayer has granted non-exclusive rights to Sun Pharma to market and distribute the second brand, Lyvelsa. The move aims to make healthcare more accessible to a larger number of patients in India.